The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | EXPEL PANC: BXC701 plus pembrolizumab in second-line advanced PDAC
Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, discusses final outcomes from the Phase II EXPEL PANC trial (NCT05558982) of BXC701 with pembrolizumab in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC). While the combination did not meet the preliminary efficacy endpoint to trigger the second stage, encouraging signs of antitumour activity were observed, with ongoing correlative studies aimed at identifying predictive markers of response and resistance. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Pancreas cancer, we’ve been trying to make immunotherapy work for a long time with really no good data to show that it works at all. So we took a patient population who had already had one line of chemotherapy and gave them pembrolizumab immunotherapy with a novel oral drug, BXC701 which is an oral dipeptidyl peptidase inhibitor, inhibits dipeptidyl peptidases 4, 8, and 9, and fibroblast activation protein FAP...
Pancreas cancer, we’ve been trying to make immunotherapy work for a long time with really no good data to show that it works at all. So we took a patient population who had already had one line of chemotherapy and gave them pembrolizumab immunotherapy with a novel oral drug, BXC701 which is an oral dipeptidyl peptidase inhibitor, inhibits dipeptidyl peptidases 4, 8, and 9, and fibroblast activation protein FAP. And we saw that in three of 19 patients, we actually saw significant tumor shrinkage. One of those patients was microsatellite instability high, but two were microsatellite stable, including one with liver metastases. And so the median progression-free survival was about a little over two months, but the overall survival on median has not yet been reached. So we’re excited that, again, excluding some patients who came off due to rapid progression, there are some folks who seem to derive some benefit from immunotherapy, which again should not work in this patient population, including three patients who were on study for six months or longer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
